Table 3. Use of medications of interest during follow-up in hospitalized COVID-19 patients.
| Medication use during follow-up | Both prior use a and follow-up use b | |
|---|---|---|
| Number of patients | 40,524 | 40,524 |
| Medication use, n (%) | ||
| Any of the medications of interest c | 38,403 (94.77) | 5,014 (12.37) |
| Anticoagulants | ||
| Any anticoagulants d | 36,824 (90.87) | 2,773 (6.84) |
| Vitamin K antagonists | 1,291 (3.19) | 229 (0.57) |
| Factor Xa inhibitors | 7,744 (19.11) | 651 (1.61) |
| UFH | 13,634 (33.64) | 983 (2.43) |
| LMWH | 28,458 (70.23) | 778 (1.92) |
| DTIs | 344 (0.85) | 24 (0.06) |
| Antiplatelets e | 15,635 (38.58) | 1,585 (3.91) |
| Aspirin | 14,798 (36.52) | 578 (1.43) |
| tPA | 2,448 (6.04) | 85 (0.21) |
| Remdesivir | 14,403 (35.54) | 26 (0.06) |
| Corticosteroids | 25,809 (63.69) | 2,083 (5.14) |
| Convalescent plasma | 3,384 (8.35) | 0 |
| Antithrombin III | 4 (0.01) | 0 |
Abbreviations: COVID-19, coronavirus 2019; DTI, direct thrombin inhibitor; LMWH, low molecular weight heparin; tPA, tissue plasminogen activator; UFH, unfractionated heparin.
a
Prior use was defined as documentation of the medication(s) of interest during the 45-day period prior to the index date.
b
Follow-up use was defined as documentation of the medication(s) of interest on or after the index date.
c
The medications of interest included anticoagulants, antiplatelets, aspirin, tPA, remdesivir, corticosteroids, convalescent plasma, and antithrombin III.
d
Anticoagulants included vitamin K antagonists, factor Xa inhibitors, UFH, LMWH, and DTIs.
e
Antiplatelet medications did not include aspirin.